170 related articles for article (PubMed ID: 34539667)
1. p53 Activation Effect in the Balance of T Regulatory and Effector Cell Subsets in Patients With Thyroid Cancer and Autoimmunity.
Arena A; Stigliano A; Belcastro E; Giorda E; Rosado MM; Grossi A; Assenza MR; Moretti F; Fierabracci A
Front Immunol; 2021; 12():728381. PubMed ID: 34539667
[TBL] [Abstract][Full Text] [Related]
2. Effect of p53 activation through targeting MDM2/MDM4 heterodimer on T regulatory and effector cells in the peripheral blood of Type 1 diabetes patients.
Pellegrino M; Traversi G; Arena A; Cappa M; Rosado MM; Andreani M; Delfino DV; Moretti F; Fierabracci A
PLoS One; 2020; 15(1):e0228296. PubMed ID: 31995625
[TBL] [Abstract][Full Text] [Related]
3. Targeting of interleukin (IL)-17A inhibits PDL1 expression in tumor cells and induces anticancer immunity in an estrogen receptor-negative murine model of breast cancer.
Ma YF; Chen C; Li D; Liu M; Lv ZW; Ji Y; Xu J
Oncotarget; 2017 Jan; 8(5):7614-7624. PubMed ID: 27935862
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Inhibitor-Induced Thyroiditis Is Associated with Increased Intrathyroidal T Lymphocyte Subpopulations.
Kotwal A; Gustafson MP; Bornschlegl S; Kottschade L; Delivanis DA; Dietz AB; Gandhi M; Ryder M
Thyroid; 2020 Oct; 30(10):1440-1450. PubMed ID: 32323619
[No Abstract] [Full Text] [Related]
5. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
[TBL] [Abstract][Full Text] [Related]
6. P53 and expression of immunological markers may identify early stage thyroid tumors.
Marcello MA; Morari EC; Cunha LL; De Nadai Silva AC; Carraro DM; Carvalho AL; Soares FA; Vassallo J; Ward LS
Clin Dev Immunol; 2013; 2013():846584. PubMed ID: 24171036
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of PD-1 and CD39 in tumor-infiltrating lymphocytes compared with peripheral blood lymphocytes in triple-negative breast cancer.
Zahran AM; Rayan A; Zahran ZAM; Mohamed WMY; Mohamed DO; Abdel-Rahim MH; El-Badawy O
PLoS One; 2022; 17(1):e0262650. PubMed ID: 35051220
[TBL] [Abstract][Full Text] [Related]
8. PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid Cancer.
Severson JJ; Serracino HS; Mateescu V; Raeburn CD; McIntyre RC; Sams SB; Haugen BR; French JD
Cancer Immunol Res; 2015 Jun; 3(6):620-30. PubMed ID: 25701326
[TBL] [Abstract][Full Text] [Related]
9. Activation of central/effector memory T cells and T-helper 1 polarization in malignant melanoma patients treated with anti-programmed death-1 antibody.
Yamaguchi K; Mishima K; Ohmura H; Hanamura F; Ito M; Nakano M; Tsuchihashi K; Ota SI; Wada N; Uchi H; Ariyama H; Kusaba H; Niiro H; Akashi K; Baba E
Cancer Sci; 2018 Oct; 109(10):3032-3042. PubMed ID: 30066977
[TBL] [Abstract][Full Text] [Related]
10. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
11. Concurrent OX40 and CD30 Ligand Blockade Abrogates the CD4-Driven Autoimmunity Associated with CTLA4 and PD1 Blockade while Preserving Excellent Anti-CD8 Tumor Immunity.
Nawaf MG; Ulvmar MH; Withers DR; McConnell FM; Gaspal FM; Webb GJ; Jones ND; Yagita H; Allison JP; Lane PJL
J Immunol; 2017 Aug; 199(3):974-981. PubMed ID: 28646041
[TBL] [Abstract][Full Text] [Related]
12. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
[TBL] [Abstract][Full Text] [Related]
13. Lymphocytic profiling in thyroid cancer provides clues for failure of tumor immunity.
Imam S; Paparodis R; Sharma D; Jaume JC
Endocr Relat Cancer; 2014 Jun; 21(3):505-16. PubMed ID: 24623740
[TBL] [Abstract][Full Text] [Related]
14. Targeting of TLRs inhibits CD4+ regulatory T cell function and activates lymphocytes in human peripheral blood mononuclear cells.
Voo KS; Bover L; Harline ML; Weng J; Sugimoto N; Liu YJ
J Immunol; 2014 Jul; 193(2):627-34. PubMed ID: 24928999
[TBL] [Abstract][Full Text] [Related]
15. Tumor suppressor p53 inhibits systemic autoimmune diseases by inducing regulatory T cells.
Kawashima H; Takatori H; Suzuki K; Iwata A; Yokota M; Suto A; Minamino T; Hirose K; Nakajima H
J Immunol; 2013 Oct; 191(7):3614-23. PubMed ID: 24006461
[TBL] [Abstract][Full Text] [Related]
16. CD4/CD8 + T cells, DC subsets, Foxp3, and IDO expression are predictive indictors of gastric cancer prognosis.
Li F; Sun Y; Huang J; Xu W; Liu J; Yuan Z
Cancer Med; 2019 Dec; 8(17):7330-7344. PubMed ID: 31631566
[TBL] [Abstract][Full Text] [Related]
17. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation.
Redin E; Garmendia I; Lozano T; Serrano D; Senent Y; Redrado M; Villalba M; De Andrea CE; Exposito F; Ajona D; Ortiz-Espinosa S; Remirez A; Bertolo C; Sainz C; Garcia-Pedrero J; Pio R; Lasarte J; Agorreta J; Montuenga LM; Calvo A
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33658304
[TBL] [Abstract][Full Text] [Related]
18. Blockade of programmed death-1 in young (New Zealand Black x New Zealand White)F1 mice promotes the suppressive capacity of CD4+ regulatory T cells protecting from lupus-like disease.
Wong M; La Cava A; Hahn BH
J Immunol; 2013 Jun; 190(11):5402-10. PubMed ID: 23636058
[TBL] [Abstract][Full Text] [Related]
19. Higher frequencies of GARP(+)CTLA-4(+)Foxp3(+) T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality.
Kalathil S; Lugade AA; Miller A; Iyer R; Thanavala Y
Cancer Res; 2013 Apr; 73(8):2435-44. PubMed ID: 23423978
[TBL] [Abstract][Full Text] [Related]
20. Human CD8
Machicote A; Belén S; Baz P; Billordo LA; Fainboim L
Front Immunol; 2018; 9():2788. PubMed ID: 30555473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]